Lupin Launches Generic Mybetriq in US, Eyes Robust Sales Growth

22 Apr 2024 , 03:21 PM

Lupin announced the launch of Mirabegron, a generic version of Mybetriq, to treat overactive bladder in the United States, following approval from the USFDA.

Mirabegron, manufactured by Astellas Pharma Global Development, is Lupin’s generic equivalent of Myrbetriq and will be produced at its facility in Nagpur, India.

Myrbetriq, a prescription medicine, is used to treat overactive bladder symptoms like frequent or urgent urination and urinary incontinence, including neurogenic detrusor overactivity (NDO) in children.

According to IQVIA MAT February 2024, Mirabegron recorded estimated annual sales of $1,019 million in the US.

Lupin’s Executive Director anticipates quarterly US sales of $200–210 million this year, with North America contributing approximately 37% to Lupin’s sales, and India accounting for around 34%.

Lupin recently launched the first generic version of Oracea (Doxycycline capsules, 40 mg) in the US, used to treat inflammatory lesions of rosacea in adult patients.

The company also successfully concluded inspections by the USFDA at its manufacturing facility in Vadodara, Gujarat.

Lupin operates globally, developing and commercializing branded and generic formulations, biotechnology products, and APIs across various markets.

Lupin shares were trading at nearly 3.21% higher on Monday at ₹1,595 apiece on the NSE, with a year-to-date surge of nearly 21.64% and a one-year gain of 127.47%.

For feedback and suggestions, write to us at [e-mail]